Zynex (OTCMKTS:ZYXI) PT Lowered to $25.00
Zynex (OTCMKTS:ZYXI) had its price target lowered by HC Wainwright from $30.00 to $25.00 in a research note released on Wednesday, The Fly reports. HC Wainwright currently has a neutral rating on the stock.
ZYXI has been the topic of a number of other reports. Zacks Investment Research upgraded shares of Zynex from a hold rating to a buy rating and set a $12.00 target price on the stock in a report on Tuesday, March 31st. B. Riley cut shares of Zynex from a buy rating to a neutral rating in a research note on Monday, July 13th. They noted that the move was a valuation call. Piper Sandler initiated coverage on shares of Zynex in a research note on Monday, July 20th. They set an overweight rating and a $30.00 target price for the company. Finally, Northland Securities cut shares of Zynex from an outperform rating to a market perform rating and set a $21.00 price objective for the company. in a research note on Tuesday, June 16th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company currently has an average rating of Buy and a consensus target price of $23.50.
Shares of ZYXI stock opened at $19.12 on Wednesday. The company’s fifty day simple moving average is $23.36 and its 200-day simple moving average is $16.05. Zynex has a 52 week low of $7.51 and a 52 week high of $29.73. The company has a market cap of $663.58 million, a PE ratio of 86.91 and a beta of 1.05.
In related news, CEO Thomas Sandgaard sold 1,250,000 shares of the stock in a transaction dated Tuesday, July 14th. The stock was sold at an average price of $22.00, for a total transaction of $27,500,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Daniel J. Moorhead acquired 2,733 shares of the company’s stock in a transaction that occurred on Thursday, July 30th. The shares were bought at an average cost of $18.11 per share, for a total transaction of $49,494.63. Following the acquisition, the chief financial officer now directly owns 19,001 shares in the company, valued at approximately $344,108.11. The disclosure for this purchase can be found here.
Several hedge funds have recently modified their holdings of ZYXI. Soleus Capital Management L.P. bought a new stake in shares of Zynex during the first quarter valued at approximately $3,859,000. EAM Global Investors LLC purchased a new position in shares of Zynex in the first quarter worth $1,666,000. EAM Investors LLC purchased a new position in shares of Zynex in the first quarter worth $1,296,000. Genesee Capital Advisors LLC bought a new stake in shares of Zynex in the second quarter worth $1,995,000. Finally, Mackay Shields LLC bought a new stake in shares of Zynex in the second quarter worth $1,953,000. Hedge funds and other institutional investors own 0.05% of the company’s stock.
Zynex, Inc, a medical technology company, designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. Its products include NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; and InWave, an electrical stimulation product for the treatment of female urinary incontinence.
Receive News & Ratings for Zynex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynex and related companies with MarketBeat.com's FREE daily email newsletter.